期刊
STEM CELL REVIEWS AND REPORTS
卷 17, 期 1, 页码 153-162出版社
SPRINGER
DOI: 10.1007/s12015-020-09999-0
关键词
COVID19; Coronavirus; SARS-CoV-2; Mesenchymal stem cells; MSC priming; Immunomodulation
The COVID19 pandemic is designated a public health crisis by WHO and is impacting countries worldwide. Using 'Primed' Mesenchymal Stem Cells (MSCs) as a therapeutic alternative may help improve responses in COVID19 patients.
The COVID19 pandemic, designated as a public health crisis by the World Health Organization (WHO), is rapidly spreading around the world impacting the health and economy of almost all the countries. The data of hospitalized COVID19 patients, especially those with serious illness, indicate the involvement of immunopathological complications. As no effective treatment is currently available, we propose 'Primed' Mesenchymal Stem Cells (MSCs) as a therapeutic alternative to tackle devastating epidemic. The individual response to MSCs treatment is heterogeneous. During the treatment of infectious pathology, the effectiveness of the treatment may vary based on the disease scenario. Interestingly, when transplanted in vivo, MSCs are governed by the locally regulated microenvironment, suggesting that the restorative variability could be tailored by choosing a priming regimen to specifically correct a given pathology. Therefore, in our opinion, the priming of MSCs could be a novel approach to improve the responses of COVID19 patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据